RNAZ

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:RNAZ

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/19	05 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/19	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/14	21 : 00	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/14	06 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/10	21 : 45	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/10	20 : 00	GlobeNewswire Inc.	Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/08	05 : 00	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/08	05 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/05/29	22 : 15	GlobeNewswire Inc.	TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/05/21	05 : 00	Edgar (US Regulatory)	Form DEFR14A - Revised definitive proxy soliciting materials	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/05/16	06 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/05/14	06 : 08	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/05/13	21 : 30	GlobeNewswire Inc.	TransCode Therapeutics Open Letter to Shareholders	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/05/11	05 : 50	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/05/11	05 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/04/15	22 : 00	GlobeNewswire Inc.	TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/04/03	22 : 10	GlobeNewswire Inc.	TransCode Therapeutics Reports 2023 Results; Provides Business Update	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/03/28	21 : 30	GlobeNewswire Inc.	TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/03/11	22 : 00	GlobeNewswire Inc.	TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/03/07	06 : 15	GlobeNewswire Inc.	TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/02/20	22 : 00	GlobeNewswire Inc.	TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/02/16	06 : 00	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/02/14	10 : 12	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/02/01	06 : 33	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/02/01	06 : 05	GlobeNewswire Inc.	Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/01/29	22 : 30	GlobeNewswire Inc.	TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/01/23	06 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/01/23	06 : 45	GlobeNewswire Inc.	TransCode Therapeutics Announces Closing of $7.25 Million Public Offering	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/01/20	11 : 57	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/01/19	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:RNAZ	TransCode Therapeutics Inc